Withdrawing aspirin post- PCI reduces major bleeding by more than half, maintaining safety and efficacy in high-risk heart patients on ticagrelor.
These are the results from the ULTIMATE-DAPT study announced during a late-breaking trial presentation at the American College of Cardiology Scientific Sessions on April 7, and published inThis is the first and only trial to test high-risk patients with recent or threatened heart attack taking ticagrelor with a placebo starting one month after PCI, and compare them with ACS patients taking ticagrelor with aspirin over the same period.
The primary efficacy endpoint of clinically-relevant bleeding, defined as BARC types 2, 3 or 5 bleeding, was assessed in the intention-to-treat population between one-month and twelve-months post-PCI in patients who were event-free after one month of ticagrelor and aspirin. Switching to ticagrelor monotherapy at one month resulted in a 55-percent reduction in the hazard of clinically relevant bleeding compared with continuing ticagrelor plus aspirin over the ensuing 11 months.
Aspirin PCI High-Risk Heart Patients Ticagrelor Bleeding Outcomes Study
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: 12News - 🏆 586. / 51 Read more »
Source: MSNBC - 🏆 469. / 51 Read more »
Source: NBCDFW - 🏆 288. / 63 Read more »
Source: dallasnews - 🏆 18. / 71 Read more »
Source: TODAYshow - 🏆 389. / 55 Read more »
Source: DailyFX - 🏆 305. / 63 Read more »